Bristol Myers Squibb struck a broad, multi-asset partnership with China’s Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs spanning the two companies’ pipelines. The deal value was disclosed as up to $15.2 billion, reflecting the growing appetite by Western drugmakers to buy into China’s R&D momentum. The transaction structure mirrors other large “portfolio” deals in oncology and beyond, with BMS gaining access to early candidates while Hengrui retains the operational benefit of funding and Western development infrastructure. The move also signals confidence that the assets can be de-risked through clinical progress and regulatory pathways. For strategy teams, the key datapoint is the scale—13 programs—reinforcing that large licensing and collaboration deals are increasingly being used to manage pipeline risk across multiple modalities and indications.